BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23319802)

  • 1. mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis.
    Zhao L; Yue P; Khuri FR; Sun SY
    Cancer Res; 2013 Mar; 73(6):1946-57. PubMed ID: 23319802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme.
    Panner A; Crane CA; Weng C; Feletti A; Parsa AT; Pieper RO
    Cancer Res; 2009 Oct; 69(20):7911-6. PubMed ID: 19808964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
    Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
    Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589.
    Kauh J; Fan S; Xia M; Yue P; Yang L; Khuri FR; Sun SY
    PLoS One; 2010 Apr; 5(4):e10376. PubMed ID: 20442774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTORC1/2 inhibitor and curcumin induce apoptosis through lysosomal membrane permeabilization-mediated autophagy.
    Seo SU; Woo SM; Lee HS; Kim SH; Min KJ; Kwon TK
    Oncogene; 2018 Sep; 37(38):5205-5220. PubMed ID: 29849119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma.
    Wang Q; Wei F; Li C; Lv G; Wang G; Liu T; Bellail AC; Hao C
    PLoS One; 2013; 8(8):e73175. PubMed ID: 23991179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Cathepsin S Induces Mitochondrial ROS That Sensitizes TRAIL-Mediated Apoptosis Through p53-Mediated Downregulation of Bcl-2 and c-FLIP.
    Seo BR; Min KJ; Woo SM; Choe M; Choi KS; Lee YK; Yoon G; Kwon TK
    Antioxid Redox Signal; 2017 Aug; 27(4):215-233. PubMed ID: 27927016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.
    Zhang T; Wang X; He D; Jin X; Guo P
    Anticancer Drugs; 2014 Sep; 25(8):887-97. PubMed ID: 24714080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells.
    Li S; Oh YT; Yue P; Khuri FR; Sun SY
    Oncogene; 2016 Feb; 35(5):642-50. PubMed ID: 25893295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells.
    Zhao L; Yue P; Lonial S; Khuri FR; Sun SY
    Mol Cancer Ther; 2011 Dec; 10(12):2415-25. PubMed ID: 21914854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel Akt inhibitor API-1 induces c-FLIP degradation and synergizes with TRAIL to augment apoptosis independent of Akt inhibition.
    Li B; Ren H; Yue P; Chen M; Khuri FR; Sun SY
    Cancer Prev Res (Phila); 2012 Apr; 5(4):612-20. PubMed ID: 22345097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
    Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
    Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.
    Zeng Z; Shi YX; Tsao T; Qiu Y; Kornblau SM; Baggerly KA; Liu W; Jessen K; Liu Y; Kantarjian H; Rommel C; Fruman DA; Andreeff M; Konopleva M
    Blood; 2012 Sep; 120(13):2679-89. PubMed ID: 22826565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein.
    Zhitao J; Long L; Jia L; Yunchao B; Anhua W
    Tumour Biol; 2015 Dec; 36(12):9621-30. PubMed ID: 26142735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ubiquitin-specific protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme.
    Panner A; Crane CA; Weng C; Feletti A; Fang S; Parsa AT; Pieper RO
    Cancer Res; 2010 Jun; 70(12):5046-53. PubMed ID: 20484045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X; Wang X; Xu T; Zhong S; Shen Z
    Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.
    Ravichandran K; Zafar I; Ozkok A; Edelstein CL
    Nephrol Dial Transplant; 2015 Jan; 30(1):45-53. PubMed ID: 25239638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
    Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F
    J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.
    Yao W; Yue P; Khuri FR; Sun SY
    Oncotarget; 2015 Oct; 6(33):34669-79. PubMed ID: 26415225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.